TLDR
- PSTV stock drops 23% intraday as the 1-for-25 reverse split nears April 2.
- Plus Therapeutics consolidates 171M shares to 6.86M in a Nasdaq move.
- Reverse splits adjust equity awards and warrants without changing ownership stakes.
- Stock opens April 2 with the new CUSIP 72941H806 after a price adjustment.
- PSTV shares may gain post-split market attention amid low-volume stabilisation.
Plus Therapeutics (PSTV) opened weaker at $0.16 after an early spike near $0.21 failed. The stock fell 23% intraday, signalling strong resistance and bearish momentum. Volume remains low as the company prepares a 1-for-25 reverse stock split effective April 2, 2026.
Reverse Stock Split and Nasdaq Compliance
The board approved the reverse stock split to increase the per-share price. The split reduces approximately 171.5 million shares to around 6.86 million. No change occurs to the par value, keeping it at $0.001 per share.
All shareholders are affected uniformly, except for fractional shares, which will be paid in cash. The company retained Broadridge Financial Services as exchange agent to manage the split. Certificate holders will receive instructions, while book-entry and broking account holders require no immediate action.
The reverse split ensures compliance with Nasdaq’s $1.00 minimum bid price requirement. It also adjusts equity awards and outstanding warrants proportionally. Investors should expect their percentage ownership to remain nearly identical post-split.
Current Stock Performance and Market Outlook
Shares show weak consolidation around $0.16 following intraday losses. Early trading failed near $0.21, highlighting strong overhead resistance. Low-volume stabilisation indicates cautious post-split market activity.
The reverse split may increase per-share market interest by raising the stock price. Traders may perceive the higher-priced shares as more appealing for institutional or retail participation. Overall liquidity might remain subdued initially but could improve after the split.
Plus Therapeutics maintains a clinical-stage pipeline targeting CNS cancers. Programs focus on leptomeningeal metastases and recurrent glioblastoma. The company integrates image-guided beta radiation with targeted drug delivery, advancing treatment options.
Company Background and Strategic Operations
Plus Therapeutics is advancing clinical-stage radiotherapeutics. Strategic partnerships enable manufacturing and potential commercial scalability. The company focuses on difficult-to-treat CNS cancers, combining technology with precision therapeutics.
The reverse split is part of a larger effort to optimise trading conditions. Broadridge will ensure a smooth transition for stockholders holding physical certificates. The adjustment aims to stabilise the company’s Nasdaq listing while maintaining shareholder equity.
Trading under the symbol PSTV will continue post-split. Shares will have a new CUSIP, 72941H806, effective April 2. This change allows the stock to trade at a higher per-share price while preserving shareholder proportions.
Plus Therapeutics continues to pursue pipeline advancement and potential market opportunities. Given the consolidated shares and modified trading price, the split may garner fresh attention. Shareholders will receive cash for fractional shares, completing the restructuring efficiently.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
